got a boost after the stock was upgraded by investment research firm Stifel Nicolaus. Analyst Edward Nash said the stock's pullback after a Food and Drug Administration request for more safety and efficacy information on Avastin in breast cancer presents an attractive entry point for investors. He believes regulators will ultimately approve the drug for that indication. Shares were up 1.2% to $78.61.
settled patent litigation and entered a licensing agreement for a generic version of the topical testosterone treatment AndroGel. Par has acquired the rights to a Food and Drug Administration application for the generic version of the drug from
, and according to the settlement, the company will be permitted to launch its generic no later than February 2016.
also reached a settlement on AndroGel patent litigation with Solvay subsidiary Unimed. Under that agreement, Watson will have nonexclusive rights to U.S. patents covering AndroGel, which it may not bring to market until another generic version is launched, or after August 2015. Par shares rose 2.9% to $19.69, and Watson was up 1% to $26.35.
shares jumped almost 10% after an announcement after the close of trading Wednesday that the company's stock would replace
in the S&P Small-Cap 600. MRO is being acquired by
. Shares rose 6.9% to $23.96.
climbed 2.4% to $68.14 after the company announced positive interim results from a clinical trial comparing its multiple sclerosis drug Campath with Rebif.
saw their shares dip despite positive news that their jointly developed diabetes drug exenatide promotes weight loss and improved blood sugar levels just as effectively as insulin treatments like
NovoMix 30 biphasic insulin. Exenatide, which also goes by the brand name Byetta, was approved in April 2005. Lilly's shares lost 15 cents, or 0.3%, to $55.06, and Amylin's stock fell 39 cents, or 0.8%, to $45.89.
Other movers included
, 1.2% lower to $43.34,
, down 2.7% to $13.45,
, whose shares sank 11.3% to $2.52, and
BioDelivery Sciences International
, off 6% to $2.03.
was gaining 7.6% to $7.70,
soared 18.6% to $29.42,
was up 8.9% to $1.71, and
rose 6.7% to $1.90.